Wednesday, August 22, 2012
Ocular Therapeutix Inc., of Bedford, Mass., said its travoprost punctum plug will be tested in a pilot Phase II trial to examine a two-month sustained-release drug (OTX-TP2) for ocular hypertension and glaucoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.